Oxford Science Enterprises

Oxford Science Enterprises is a venture firm based in Oxford, United Kingdom, established in 2015 in partnership with the University of Oxford. The firm focuses on building and investing in companies that develop fundamental technologies aimed at addressing significant global challenges. Its investment areas include life sciences, healthcare, artificial intelligence, software, and deep tech, targeting issues such as nuclear fusion, quantum computing, and the development of treatments for infectious diseases. By leveraging its extensive experience and a robust network of investors, entrepreneurs, and sector experts, Oxford Science Enterprises aims to foster a world-class technology ecosystem and support the growth of innovative science-based businesses.

Claire Brown

Partner ( Life Sciences)

Sally Dewhurst

Principal, Life Sciences

Sam Harman

Senior investment associate

Sanne de Jongh

Partner, Life Sciences

James Wong

Principal, Life Sciences

Alexis Zervoglos

Senior Partner, Technology

George Todd

Senior Associate, Deep Tech

Katya Smirnyagina Ph.D

Senior Partner, Life Sciences

Liliane Chamas Ph.D

Principal, Health Tech

Oliver Mahony

Principal

Past deals in United Kingdom

Alloyed

Series B in 2025
Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Mixergy

Venture Round in 2025
Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

Iota Sciences

Venture Round in 2024
Iota Sciences Ltd. is a company based in Oxford, United Kingdom, founded in 2016. It specializes in developing and delivering innovative tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. The company focuses on creating fluidic mu-wells specifically designed for cell biology applications, aiming to advance research and discovery in this field. Through its unique capabilities, Iota Sciences seeks to facilitate significant advancements in the understanding and manipulation of cellular systems.

PQShield

Series B in 2024
PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Theolytics

Venture Round in 2024
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Sitryx Therapeutics

Series A in 2023
Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Navenio

Series A in 2023
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Theolytics

Series A in 2023
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Caristo Diagnostics

Series A in 2023
Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Mixergy

Venture Round in 2023
Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

Mind Foundry

Series B in 2023
Mind Foundry Limited, headquartered in Oxford, United Kingdom, was founded in 2015 and specializes in developing software that helps organizations extract valuable insights from their data. As a spin-off from Oxford University, Mind Foundry combines innovation with usability through its Responsible AI platform, which addresses significant real-world challenges across various sectors, including insurance, infrastructure, and defense. The company’s technologies apply machine learning and advanced algorithmic modeling to enhance decision-making and problem-solving capabilities for clients. Founded by noted AI and machine learning experts, Mind Foundry aims to foster collaboration between humans and AI, promoting responsible and transparent AI usage while tackling pressing issues such as insurance fraud detection and complex signal processing.

Osler Diagnostics

Series C in 2022
Osler Diagnostics is a UK-based company focused on providing accessible health diagnostics. Established in 2017 from research at the University of Oxford, Osler has developed the Osler Origin, a portable laboratory capable of delivering lab-quality diagnostics anywhere, anytime. This innovative device requires only a drop of blood to test for a wide range of biomarkers, allowing users to monitor various health markers conveniently. Osler aims to serve diverse healthcare settings globally, empowering individuals to understand and manage their health more effectively. The company is headquartered in Oxford, UK.

Nucleome Therapeutics

Series A in 2022
Nucleome Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on transforming drug discovery by decoding the complexities of the human genome. Founded in 2019, the company utilizes a unique genomics platform that leverages the three-dimensional structure of the genome and machine learning to explore the vast, largely uncharted regions of the genome, often referred to as the dark matter. This area contains over 95% of disease-linked genetic variants, providing significant opportunities for identifying new therapeutic targets. Nucleome Therapeutics specializes in creating high-resolution genome structure maps and validating genetic variants in primary cell types, facilitating the discovery and development of novel precision medicines. The company's initial emphasis is on lymphocytes and autoimmune diseases, with the goal of establishing a robust pipeline of drug candidates and corresponding biomarkers. Founded by experts in gene regulation from the University of Oxford, Nucleome is backed by investments from Oxford Sciences Innovation.

BibliU

Series B in 2022
BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

MoA Technology

Series B in 2022
MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was incorporated in 2017. It was spun out from the University of Oxford and focuses on developing innovative agricultural technologies aimed at enabling farmers to produce healthy food through sustainable crop systems. The company leverages research led by Professor Liam Dolan to discover new methods that enhance agricultural productivity while promoting sustainability.

OMass Therapeutics

Series B in 2022
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

First Light Fusion

Series C in 2022
First Light Fusion Limited, founded in 2011 and based in Begbroke, United Kingdom, specializes in advanced implosion processes for electricity generation through inertial confinement fusion. The company originated as a spin-out from the University of Oxford and actively engages in researching and developing sustainable renewable energy solutions. It employs a team of engineers and physicists and collaborates with several academic institutions, including the University of Oxford, Warwick University, UCL, and Imperial College London. First Light Fusion focuses on harnessing fundamental physics to discover new energy sources, utilizing detailed numerical simulations and experimental validation in its research efforts.

PQShield

Series A in 2022
PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Navenio

Venture Round in 2021
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

PepGen

Venture Round in 2021
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Orbit Discovery

Venture Round in 2021
Orbit Discovery Ltd. is a biotechnology company specializing in peptide display technology to discover peptide drugs for chronic diseases. Established in 2015 and based in Oxford, United Kingdom, the company utilizes an innovative in vitro bead display platform that links randomized peptide sequences to their encoding DNA. This technology enables high-throughput screening of peptides, facilitating the identification and optimization of potential drug candidates. By combining the specificity and efficacy of large biologic molecules with the advantages of small molecules, such as lower manufacturing costs and simpler delivery methods, Orbit Discovery aims to address a wide range of chronic diseases affecting large patient populations. The company's focus is on both internal drug discovery programs and collaborative research efforts, streamlining the discovery process and accelerating the development of new peptide therapeutics.

Caristo Diagnostics

Venture Round in 2021
Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Evox Therapeutics

Series C in 2021
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

SpyBiotech

Series A in 2021
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

Theolytics

Series A in 2021
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Living Optics

Seed Round in 2021
Living Optics Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the design and development of compact hyperspectral imaging cameras and related software. The company's innovative technology captures data that is not visible to the human eye or traditional cameras, making hyperspectral imaging more accessible and affordable for a variety of applications in consumer products, medical devices, and the manufacturing industry. Living Optics aims to empower computer vision developers and scientists by providing portable solutions that enable the integration of spectral imaging data into new research and applications. In September 2022, the company secured $25 million in Series A funding to further its mission of revolutionizing the imaging market.

DJS Antibodies

Venture Round in 2020
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, focuses on the design and discovery of novel therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company specializes in developing innovative therapeutics aimed at treating chronic inflammatory diseases, utilizing breakthrough technology to create first-in-class antibodies against challenging disease targets. By isolating high-quality antibodies against complex protein targets that have previously proven difficult for drug discovery, DJS Antibodies aims to provide effective treatments for conditions that are currently undruggable and untreatable.

PepGen

Series A in 2020
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Refeyn

Series A in 2020
Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry technology for the analysis of biomolecules. The company's flagship product, Refeyn One, employs single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. This innovative optical technology allows researchers to measure the mass of individual molecules in their native state without the necessity for labels, providing both quality-control instruments and advanced research tools. Refeyn's offerings enable scientists to conduct mass measurements across a range of biologically relevant concentrations, enhancing the capabilities of biomolecular analysis.

PQShield

Seed Round in 2020
PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Oxford Flow

Venture Round in 2020
Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.

Navenio

Series A in 2020
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

BibliU

Series A in 2020
BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

Living Optics

Seed Round in 2020
Living Optics Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the design and development of compact hyperspectral imaging cameras and related software. The company's innovative technology captures data that is not visible to the human eye or traditional cameras, making hyperspectral imaging more accessible and affordable for a variety of applications in consumer products, medical devices, and the manufacturing industry. Living Optics aims to empower computer vision developers and scientists by providing portable solutions that enable the integration of spectral imaging data into new research and applications. In September 2022, the company secured $25 million in Series A funding to further its mission of revolutionizing the imaging market.

OMass Therapeutics

Series A in 2020
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Oxford VR

Series A in 2020
Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.

Alloyed

Series B in 2020
Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Mixergy

Series A in 2019
Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

MoA Technology

Series A in 2019
MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was incorporated in 2017. It was spun out from the University of Oxford and focuses on developing innovative agricultural technologies aimed at enabling farmers to produce healthy food through sustainable crop systems. The company leverages research led by Professor Liam Dolan to discover new methods that enhance agricultural productivity while promoting sustainability.

Zegami

Series B in 2019
Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

Zegami

Series B in 2019
Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

OMass Therapeutics

Series A in 2018
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Alloyed

Series A in 2018
Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Covatic

Funding Round in 2018
Covatic Ltd, established in 2016 and headquartered in Birmingham, United Kingdom, specializes in broadcast personalization software. The company's innovative platform employs mobile-based algorithms to enhance user experience by delivering personalized content without compromising personal data. By identifying optimal engagement moments and methods for individuals, Covatic enables clients to effectively connect with their target audiences. This approach allows for the collection and personalization of insights, ultimately improving the way applications serve their users. With an emphasis on problem-solving, Covatic continues to develop solutions that enhance app functionality and user interaction.

Caristo Diagnostics

Seed Round in 2018
Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Oxford VR

Venture Round in 2018
Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.

Evox Therapeutics

Series B in 2018
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

BioBeats

Seed Round in 2018
BioBeats, established in 2012 and headquartered in London, specializes in digital health solutions for personal wellness. The company leverages artificial intelligence and real-time data from smartphones and wearables to tackle global mental health challenges. By fusing research from the University of Oxford, BioBeats creates AI products that track neurological and physiological correlates to psychological progress, predict disorder onset, and provide personalized support. Their psychological wellness application calculates a baseline wellbeing score and offers insights into stress responses, enabling users to identify harmful patterns and improve their overall mental health.

BibliU

Seed Round in 2018
BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

Orbit Discovery

Series A in 2018
Orbit Discovery Ltd. is a biotechnology company specializing in peptide display technology to discover peptide drugs for chronic diseases. Established in 2015 and based in Oxford, United Kingdom, the company utilizes an innovative in vitro bead display platform that links randomized peptide sequences to their encoding DNA. This technology enables high-throughput screening of peptides, facilitating the identification and optimization of potential drug candidates. By combining the specificity and efficacy of large biologic molecules with the advantages of small molecules, such as lower manufacturing costs and simpler delivery methods, Orbit Discovery aims to address a wide range of chronic diseases affecting large patient populations. The company's focus is on both internal drug discovery programs and collaborative research efforts, streamlining the discovery process and accelerating the development of new peptide therapeutics.

PQShield

Seed Round in 2018
PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Oxford Flow

Venture Round in 2018
Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.

Xerion Healthcare

Venture Round in 2018
Xerion Healthcare Limited, founded in 2015 and based in Thame, United Kingdom, specializes in developing and commercializing innovative nanoparticle treatments aimed at improving cancer care. The company focuses on utilizing titanium dioxide nanoparticles, which are injected into tumors prior to standard radiotherapy. This method enhances the effectiveness of radiotherapy by amplifying the dose of free radicals generated by X-rays, allowing for more effective treatment of dense tumors. Xerion Healthcare is currently advancing its technology for head, neck, and pancreatic cancers, with the goal of improving patient outcomes while minimizing side effects associated with conventional cancer treatments.

Latent Logic

Seed Round in 2018
Latent Logic, originally known as Morpheus Labs, was founded as a spin-off from Oxford University’s machine learning department and became a key player in the field of artificial intelligence before being acquired by Waymo in December 2019. The company specializes in advanced deep reinforcement learning techniques that empower robots and autonomous systems to learn complex tasks through demonstration. Its primary focus is on developing realistic models of road users for autonomous vehicles, enhancing the capabilities of driving simulators. By integrating computer vision with learning from demonstration, Latent Logic enables clients to create more intelligent and realistic simulations for testing autonomous control systems, ultimately contributing to the safety and efficiency of autonomous driving technologies.

Bodle Technologies

Series A in 2018
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which uses phase-change materials. This innovative display offers ultra-high resolution, vivid color, and video capability, consuming zero energy for static image storage. Bodle's reflective displays are designed for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor or sunlight conditions. Additionally, the company develops smart windows and security coatings that employ color-changing techniques, enhancing the durability and security of currencies, ID cards, and official documentation.

PepGen

Seed Round in 2018
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Theolytics

Seed Round in 2017
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Navenio

Seed Round in 2017
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

First Light Fusion

Venture Round in 2017
First Light Fusion Limited, founded in 2011 and based in Begbroke, United Kingdom, specializes in advanced implosion processes for electricity generation through inertial confinement fusion. The company originated as a spin-out from the University of Oxford and actively engages in researching and developing sustainable renewable energy solutions. It employs a team of engineers and physicists and collaborates with several academic institutions, including the University of Oxford, Warwick University, UCL, and Imperial College London. First Light Fusion focuses on harnessing fundamental physics to discover new energy sources, utilizing detailed numerical simulations and experimental validation in its research efforts.

Mind Foundry

Seed Round in 2017
Mind Foundry Limited, headquartered in Oxford, United Kingdom, was founded in 2015 and specializes in developing software that helps organizations extract valuable insights from their data. As a spin-off from Oxford University, Mind Foundry combines innovation with usability through its Responsible AI platform, which addresses significant real-world challenges across various sectors, including insurance, infrastructure, and defense. The company’s technologies apply machine learning and advanced algorithmic modeling to enhance decision-making and problem-solving capabilities for clients. Founded by noted AI and machine learning experts, Mind Foundry aims to foster collaboration between humans and AI, promoting responsible and transparent AI usage while tackling pressing issues such as insurance fraud detection and complex signal processing.

Alloyed

Seed Round in 2017
Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Zegami

Series A in 2017
Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

Diffblue

Series A in 2017
Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

SpyBiotech

Seed Round in 2017
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

Bodle Technologies

Seed Round in 2017
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which uses phase-change materials. This innovative display offers ultra-high resolution, vivid color, and video capability, consuming zero energy for static image storage. Bodle's reflective displays are designed for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor or sunlight conditions. Additionally, the company develops smart windows and security coatings that employ color-changing techniques, enhancing the durability and security of currencies, ID cards, and official documentation.

BibliU

Seed Round in 2017
BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

Covatic

Series A in 2017
Covatic Ltd, established in 2016 and headquartered in Birmingham, United Kingdom, specializes in broadcast personalization software. The company's innovative platform employs mobile-based algorithms to enhance user experience by delivering personalized content without compromising personal data. By identifying optimal engagement moments and methods for individuals, Covatic enables clients to effectively connect with their target audiences. This approach allows for the collection and personalization of insights, ultimately improving the way applications serve their users. With an emphasis on problem-solving, Covatic continues to develop solutions that enhance app functionality and user interaction.

Oxford VR

Seed Round in 2017
Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.

EnzBond

Seed Round in 2016
EnzBond Ltd is a UK-based company founded in 2016 that specializes in the optimization of biocatalysts for small molecule production. The company has created an automated in silico platform that significantly enhances the enzyme discovery process, reducing both costs and time dramatically. This proprietary technology enables rapid optimization and accurate predictions of enzyme activity, allowing the chemical industry to efficiently screen thousands of enzyme variants. By streamlining the discovery process, EnzBond aims to transform the landscape of biocatalysis and improve the production efficiency for various applications.

DJS Antibodies

Seed Round in 2016
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, focuses on the design and discovery of novel therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company specializes in developing innovative therapeutics aimed at treating chronic inflammatory diseases, utilizing breakthrough technology to create first-in-class antibodies against challenging disease targets. By isolating high-quality antibodies against complex protein targets that have previously proven difficult for drug discovery, DJS Antibodies aims to provide effective treatments for conditions that are currently undruggable and untreatable.

Argonaut Therapeutics

Seed Round in 2016
Argonaut Therapeutics Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing epigenetically acting drugs for cancer treatment. The company focuses on targeting abnormal arginine methylation, a modification linked to cancer progression, by utilizing pioneering research from the University of Oxford. Argonaut aims to create precision cancer medicines that reprogram cancer cells to trigger the body's natural cell death processes. This innovative approach seeks to provide advanced treatment options that may enhance patient recovery and improve outcomes in cancer therapy.

Iota Sciences

Seed Round in 2016
Iota Sciences Ltd. is a company based in Oxford, United Kingdom, founded in 2016. It specializes in developing and delivering innovative tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. The company focuses on creating fluidic mu-wells specifically designed for cell biology applications, aiming to advance research and discovery in this field. Through its unique capabilities, Iota Sciences seeks to facilitate significant advancements in the understanding and manipulation of cellular systems.

Osler Diagnostics

Seed Round in 2016
Osler Diagnostics is a UK-based company focused on providing accessible health diagnostics. Established in 2017 from research at the University of Oxford, Osler has developed the Osler Origin, a portable laboratory capable of delivering lab-quality diagnostics anywhere, anytime. This innovative device requires only a drop of blood to test for a wide range of biomarkers, allowing users to monitor various health markers conveniently. Osler aims to serve diverse healthcare settings globally, empowering individuals to understand and manage their health more effectively. The company is headquartered in Oxford, UK.

Oxford Impedance Diagnostics

Seed Round in 2016
Oxford Impedance Diagnostics Limited is a company that specializes in the research, design, and marketing of diagnostic tests aimed at measuring clinical biomarkers. Founded in 2016 and based in Oxford, United Kingdom, the company focuses on providing solutions that facilitate personalized medicine, enhance early risk detection, and support disease diagnosis and management. Its innovative products are intended to reduce healthcare costs while improving patient outcomes, contributing to more effective healthcare practices.

OMass Therapeutics

Seed Round in 2016
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Evox Therapeutics

Series A in 2016
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

Diffblue

Seed Round in 2016
Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

Mind Foundry

Seed Round in 2016
Mind Foundry Limited, headquartered in Oxford, United Kingdom, was founded in 2015 and specializes in developing software that helps organizations extract valuable insights from their data. As a spin-off from Oxford University, Mind Foundry combines innovation with usability through its Responsible AI platform, which addresses significant real-world challenges across various sectors, including insurance, infrastructure, and defense. The company’s technologies apply machine learning and advanced algorithmic modeling to enhance decision-making and problem-solving capabilities for clients. Founded by noted AI and machine learning experts, Mind Foundry aims to foster collaboration between humans and AI, promoting responsible and transparent AI usage while tackling pressing issues such as insurance fraud detection and complex signal processing.

Mixergy

Seed Round in 2016
Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

Navenio

Seed Round in 2016
Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Oxford Flow

Seed Round in 2016
Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.

Bodle Technologies

Seed Round in 2015
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which uses phase-change materials. This innovative display offers ultra-high resolution, vivid color, and video capability, consuming zero energy for static image storage. Bodle's reflective displays are designed for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor or sunlight conditions. Additionally, the company develops smart windows and security coatings that employ color-changing techniques, enhancing the durability and security of currencies, ID cards, and official documentation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.